PTAB Throws Out United Therapeutics Remodulin Patent in Win for SteadyMed

The PTO’s Patent Trial and Appeal Board ruled in favor of SteadyMed in the drug manufacturer’s challenge to a patent held by United Therapeutics over its Remodulin blood pressure drug.
Source: Drug Industry Daily